In silico Rivaroxaban binding affinity to β-ketoacyl[ACP]synthase I: search for new pharmacophore

The activity of Rivaroxaban as a representative of oxazolidinone series in relation to β-ketoacyl[ACP]synthase I has been studied in silico. Using the molecular docking methods, the binding sites of Rivaroxaban with protein have been identified. For the site providing the highest affinity of Rivaroxaban with protein (-10.26 kcal/mol), 4 clusters characterized by a number of runs greater than 15 have been analyzed. It was found that the specific position of the ligand within these clusters can be changed via mechanism providing a physiological response. Slight changes in the characteristics of the environment can lead to a transition from an energetically dominant position (BE = –10.26 kcal/mol) with predominantly hydrophobic interactions to another position (BE = –8.88 kcal/mol) with predominantly hydrophilic interactions. Dynamic transition discussed may cause a physiological response. The results of the study with a high degree of probability confirm the implementation of a specific mechanism of antimycobacterial action of Rivaroxaban through inhibition of the mycolate biosynthesis.

1. Francesco P., Dal Canto G., Veronese P., Esposito S. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid Microorganisms, 2021, vol. 9, no. 5, pp. 1074. https://doi.org/10.3390/microorganisms9051074

2. Marrakchi H., Laneelle M. A., Daffe M. Mycolic acids: Structures, biosynthesis, and beyond. Chemistry & Biology, 2014, vol. 21, no. 1, pp. 67–85. https://doi.org/10.1016/j.chembiol.2013.11.011

3. Dulberger C. L., Rubin E. J., Boutte C. C. The mycobacterial cell envelope – a moving target. Nature Reviews Microbiology, 2020, vol. 18, pp. 47–59. https://doi.org/10.1038/s41579-019-0273-7

4. Abrahams K. A., Besra G. S. Mycobacterial drug discovery. RSC Medicinal Chemistry, 2020, vol. 11, pp. 1354–1365. https://doi.org/10.1039/D0MD00261E

5. Schaeffer M. L., Agnihotri G., Volker C. Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB. Journal of Biological Chemistry, 2001, vol. 276, pp. 47029–47037. https://doi.org/10.1074/jbc.M108903200

6. Brown A. K., Taylor R. C., Bhatt A., Futterer K., Besra G. S. Platensimycin activity against mycobacterial beta-ketoacyl-ACP synthases. PLoS ONE, 2009, vol. 4, no. 7, e6306. https://doi.org/10.1371/journal.pone.0006306

7. Luckner S. R., Machutta C. A., Tonge P. J., Kisker C. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin. Structure, 2009, vol. 17, no. 7, pp. 1004–1013. https://doi.org/10.1016/j.str.2009.04.012

8. Bommineni G. R., Kapilashrami K., Cummings J. E., Lu Y., Knudson S. E., Gu C., et al. Thiolactomycin-based inhibitors of bacterial beta-ketoacyl-ACP synthases with in vivo activity. Journal of Medicinal Chemistry, 2016, vol. 59, pp. 5377–5390. https://doi.org/10.1021/acs.jmedchem.6b00236

9. Kumar P., Capodagli G. C., Awasthi D., Shrestha R., Maharaja K., Sukheja P., et al. Synergistic lethality of a binary inhibitor of Mycobacterium tuberculosis KasA. mBio, 2018, vol. 9, no. 6, e02101–e02117. https://doi.org/10.1128/mBio.02101-17

10. Inoyama D., Awasthi D., Capodagli G. C., Tsotetsi K., Sukheja P., Zimmerman M., et al. A preclinical candidate targeting Mycobacterium tuberculosis KasA. Cell Chemical Biology, 2020, vol. 27, pp. 560–570. https://doi.org/10.1016/j.chembiol.2020.02.007

11. Lakhvich T. T., Zushchik P. Yu., Lakhvich T. A. Rational design of the model of acyclic analogues of hydroxyisonipecotic acids. BGMU v avangarde meditsinskoi nauki i praktiki: sb. nauch. tr. [Advances in medicine and medical sciences: collection collection of scientific papers]. Minsk: Belarusian state medical university, 2019, Iss. 9, pp. 389–399 (in Russian).

12. Lakhvich T. T., Borava M. I. SAR studies on KasA: aldonamide-receptor affinity in context of TB drug design. BGMU v avangarde meditsinskoi nauki i praktiki: sb. nauch. tr. [Advances in medicine and medical sciences: collection collection of scientific papers]. Minsk: Belarusian state medical university, 2021, Iss. 11, pp. 518–523 (in Russian).

13. Morris G. M., Huey R., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S., Olson A. J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. Computational Chemistry, 2009, no. 16, pp. 2785–2791. https://doi.org/10.1002/jcc.21256

14. European Medicines Agency. Assessment report Xarelto Rivaroxaban. Available at: https://www.ema.europa.eu/en/documents/variation-report/xarelto-h-c-944-x-0010-epar-assessment-report-extension_en.pdf (accessed 01June 2022).